O verexpression of vascular endothelial growth factor (VEGF) appears important in the pathogenesis of retinopathy of prematurity (ROP). Bevacizumab (Avastin; Genentech, Inc, South San Francisco, California) is a recombinant humanized monoclonal IgG1 antibody. It binds to and inhibits the biological activity of human VEGF.
There was no inflammation in the anterior chamber, iris, choroid, optic nerve, or sclera (Figure 1) , confirmed by immunohistochemistry using markers for T and B lymphocytes (CD3, CD5, CD43, and L26) and histiocytes (CD68) (Figure 2) . All of the retinal layers were morphologically normal without inflammation, degeneration, extensive apoptosis (Figure 1 ), or necrosis as confirmed by caspase 3, glial fibrillary acidic protein, and vimentin immunostain. The retinal vessels extended to medium zone 2 of the retina as shown by CD31, CD34, and factor VIII antibodies (Figure 2 ). Few vascularization tufts through the internal limiting membrane into the vitreous were seen at the junction posterior and medium zone 2, some surrounded by histiocytes (Figure 2 ), but no preretinal fibrovascular membrane was seen and vascularization had proceeded anteriorly. Expression of VEGF in the retina and other ocular tissues was detected at both protein and messenger RNA levels ( Figure 2 ).
Comment. Bevacizumab in this patient was shown to be well tolerated without any signs of toxic effects; in particular, no inflammation, degeneration, or necrosis was observed. Furthermore, the results show that bevacizumab effectively controlled the neovascularization in zone 1, stage 2ϩ ROP. Vascular endothelial growth factor is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. 3 The retina and the proliferating abnormal vessels showed high levels of VEGF expression at both messenger RNA and protein levels. Vascular endothelial growth factor has recently been shown to influence neuronal growth, differentiation, and survival owing to its neurotrophic effects. [3] [4] [5] Therefore, the dosage of bevacizumab is critical to preserve this effect on the neuroretina for adequate development. In our case, we administered 40% of the adult dose twice. Our results show preservation of morphology and expression of VEGF in the retina. 
I
n congenital glaucoma, larger degrees of corneal distention are better tolerated by the epithelium and stroma than by the Descemet membrane. A sequential ultrasound biomicroscopical (UBM) examination of the cornea helps demonstrate both the pathophysiological mechanism for the development of breaks in the Descemet membrane as well as an accompanying clefting of stromal tissue causing acute corneal hydrops. Such examinations can provide warning of impending ruptures affecting visual prognosis.
As recently demonstrated via UBM by Nakagawa and colleagues, 1 rupture of the Descemet membrane in keratoconus is also often accompanied by clefting of the stro- Centered beneath where the overlying epithelium edema is greatest, there appears to be a decreased reflectivity of both the posterior stromal surface (arrow) and the endothelium with the Descemet membrane. Topical pressure-lowering medications were prescribed while the contralateral eye underwent a trabeculectomy procedure.
